Latest Licensing News

Black Canyon has won a $264,800 WA government grant to fund a detailed gravity survey and deep RC drilling at its Wandanya manganese project, accelerating its path to a maiden resource estimate.

Resouro Strategic Metals has unveiled a robust Preliminary Economic Assessment for its Tiros Titanium and Rare Earths Project, signalling a post-tax NPV of US$715 million and a 44.2% IRR over 20 years. Meanwhile, binding agreements for mining and processing at the Novo Mundo Gold Project promise to unlock additional value.

Clime Investment Management has wrapped up major strategic initiatives including fund sales and business consolidations, while its flagship Clime Capital fund outperformed benchmarks. The company declared a fully franked interim dividend of 0.3 cents per share.

Brazilian Critical Minerals releases a robust Bankable Feasibility Study for its Ema Rare Earth Project, highlighting a US$1.47 billion post-tax NPV and a swift 0.5-year payback period, underpinned by low capital and operating costs.

Vanguard Investments Australia has released estimated distribution amounts for 34 ETFs, covering a broad spectrum of asset classes, with payments scheduled for mid-July 2026.

Tivan Limited has engaged Indigenous-owned MDM Mining & Civil under an Early Contractor Involvement contract to optimise the access road design for its Speewah Fluorite Project in WA, supporting the ongoing Definitive Feasibility Study.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Toubani Resources (ASX: TRE) is acquiring a near 20% equity interest in Avanti Gold (CSE: AGC) via a share swap, gaining exposure to the Misisi Gold Project in the DRC with a 3.1 million ounce inferred resource.

Environmental Clean Technologies (ASX: ECT) has submitted detailed data to the US EPA showcasing its Rapid Electrothermal Mineralisation (REM) technology's ability to destroy PFAS with over 99% efficacy and full fluorine mass balance, aiming to meet stringent regulatory standards.

Alcidion confirms FY26 revenue above $50 million and EBITDA over $5 million, completing the Kyra flow products acquisition from Telstra Health to expand its patient flow solutions in ANZ and the UK.

Neuren’s partner Acadia secures positive CHMP opinion for DAYBU® in Rett syndrome, paving the way for first EU treatment approval and triggering significant milestone payments for Neuren.

Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.